lymphoma

[Foundation Medicine, Inc.] Foundation Medicine, Inc. announced that it has received approval from the US FDA for FoundationOne®CDx to be used as a companion diagnostic for ALUNBRIG®, which is currently FDA-approved for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.

[Leukemia] Scientists utilized mass cytometry and single-cell transcriptome analysis to identify several expanded populations within the angioimmunoblastic T-cell lymphoma tumor microenvironment.

[Laboratory Investigation] The authors investigated the role of hypoxia/serum deprivation-induced M1-type macrophage-derived exosomes on bone marrow MSC viability, migration, and apoptosis.

[Haematologica] Tafasitamab combined with the immunomodulatory drug lenalidomide was clinically active with a good tolerability profile in the open-label, single-arm, phase II L-MIND study of autologous stem-cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.

[Kite] Kite, a Gilead Company announced top-line results from the primary analysis of ZUMA-7, a randomized Phase III global, multicenter study showing superiority of Yescarta® compared to standard of care in second-line relapsed or refractory large B-cell lymphoma.

[Oncoimmunology] Researchers deeply investigated the impact of KIR, HLA class I, and CD16 genotypes on rituximab-dependent NK cell responses in both an in vitro cellular model from healthy blood donors and ex vivo rituximab-treated non-Hodgkin lymphoma patients.